458 related articles for article (PubMed ID: 32258135)
41. Liquid Biopsy Technique May Allow Early Screening.
Cancer Discov; 2017 Nov; 7(11):1207. PubMed ID: 28903989
[TBL] [Abstract][Full Text] [Related]
42. Clinical Applications of Liquid Biopsy in Colorectal Cancer Screening: Current Challenges and Future Perspectives.
Galoș D; Gorzo A; Balacescu O; Sur D
Cells; 2022 Nov; 11(21):. PubMed ID: 36359889
[TBL] [Abstract][Full Text] [Related]
43. Clinical utility versus futility: a tipping point for liquid biopsies in bladder cancer.
Kouba E; Cheng L
Future Oncol; 2019 Nov; 15(33):3751-3753. PubMed ID: 31651200
[No Abstract] [Full Text] [Related]
44. [Progress of circulating tumor DNA in the clinical management of colorectal cancer].
Jiang ZY; Fu W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Mar; 27(3):287-294. PubMed ID: 38532593
[TBL] [Abstract][Full Text] [Related]
45. Circulating Tumor DNA: A Step into the Future of Cancer Management.
Fernandes Marques J; Pereira Reis J; Fernandes G; Hespanhol V; Machado JC; Costa JL
Acta Cytol; 2019; 63(6):456-465. PubMed ID: 30852572
[TBL] [Abstract][Full Text] [Related]
46. Liquid Biopsy: General Concepts.
Poulet G; Massias J; Taly V
Acta Cytol; 2019; 63(6):449-455. PubMed ID: 31091522
[TBL] [Abstract][Full Text] [Related]
47. Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer.
Nordgård O; Tjensvoll K; Gilje B; Søreide K
Br J Surg; 2018 Jan; 105(2):e110-e120. PubMed ID: 29341153
[TBL] [Abstract][Full Text] [Related]
48. Opportunities, Challenges, and Prospects in Electrochemical Biosensing of Circulating Tumor DNA and its Specific Features.
Campuzano S; Serafín V; Gamella M; Pedrero M; Yáñez-Sedeño P; Pingarrón JM
Sensors (Basel); 2019 Aug; 19(17):. PubMed ID: 31480367
[TBL] [Abstract][Full Text] [Related]
49. Circulating tumor DNA as a biomarker in metastatic colorectal carcinoma case report.
Menclová K; Pudil J; Benešová L; Hálková T; Ptáčková R; Semyakina A; Minárik M; Levý M; Šimša J; Pazdírek F; Hoch J; Bláha M; Ryska M
Rozhl Chir; 2020; 99(4):179-182. PubMed ID: 32545981
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of miR-15b decreases cell migration and metastasis in colorectal cancer.
Li J; Chen Y; Guo X; Zhou L; Jia Z; Tang Y; Lin L; Liu W; Ren C
Tumour Biol; 2016 Jul; 37(7):8765-73. PubMed ID: 26743779
[TBL] [Abstract][Full Text] [Related]
51. Colorectal cancer-associated ~ 6 kDa hyaluronan serves as a novel biomarker for cancer progression and metastasis.
Zhang G; Lu R; Wu M; Liu Y; He Y; Xu J; Yang C; Du Y; Gao F
FEBS J; 2019 Aug; 286(16):3148-3163. PubMed ID: 31004406
[TBL] [Abstract][Full Text] [Related]
52. Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer.
Yu H; Han L; Yuan J; Sun Y
Cancer Biomark; 2020; 27(1):29-37. PubMed ID: 31658042
[TBL] [Abstract][Full Text] [Related]
53. The current status of the clinical utility of liquid biopsies in cancer.
Snow A; Chen D; Lang JE
Expert Rev Mol Diagn; 2019 Nov; 19(11):1031-1041. PubMed ID: 31482746
[No Abstract] [Full Text] [Related]
54. Liquid biopsy for the detection of clinical biomarkers in early breast cancer: new insights and challenges.
Matsutani A; Udagawa C; Matsunaga Y; Nakamura S; Zembutsu H
Pharmacogenomics; 2020 Apr; 21(5):359-367. PubMed ID: 32284011
[TBL] [Abstract][Full Text] [Related]
55. Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.
Li J; Han X; Yu X; Xu Z; Yang G; Liu B; Xiu P
J Exp Clin Cancer Res; 2018 Sep; 37(1):213. PubMed ID: 30176913
[TBL] [Abstract][Full Text] [Related]
56. [Moving towards a personalized oncology: The contribution of genomic techniques and artificial intelligence in the use of circulating tumor biomarkers].
Perrier A; Hainaut P; Guenoun A; Nguyen DP; Lamy PJ; Guerber F; Troalen F; Denis JA; Boissan M
Bull Cancer; 2022 Feb; 109(2):170-184. PubMed ID: 35034786
[TBL] [Abstract][Full Text] [Related]
57. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
Dasari A; Morris VK; Allegra CJ; Atreya C; Benson AB; Boland P; Chung K; Copur MS; Corcoran RB; Deming DA; Dwyer A; Diehn M; Eng C; George TJ; Gollub MJ; Goodwin RA; Hamilton SR; Hechtman JF; Hochster H; Hong TS; Innocenti F; Iqbal A; Jacobs SA; Kennecke HF; Lee JJ; Lieu CH; Lenz HJ; Lindwasser OW; Montagut C; Odisio B; Ou FS; Porter L; Raghav K; Schrag D; Scott AJ; Shi Q; Strickler JH; Venook A; Yaeger R; Yothers G; You YN; Zell JA; Kopetz S
Nat Rev Clin Oncol; 2020 Dec; 17(12):757-770. PubMed ID: 32632268
[TBL] [Abstract][Full Text] [Related]
58. Current and future perspectives of liquid biopsies in genomics-driven oncology.
Heitzer E; Haque IS; Roberts CES; Speicher MR
Nat Rev Genet; 2019 Feb; 20(2):71-88. PubMed ID: 30410101
[TBL] [Abstract][Full Text] [Related]
59. Circulating tumor DNA testing in advanced non-small cell lung cancer.
Moding EJ; Diehn M; Wakelee HA
Lung Cancer; 2018 May; 119():42-47. PubMed ID: 29656751
[TBL] [Abstract][Full Text] [Related]
60. Liquid biopsy in colorectal cancer: No longer young, but not yet old.
Roviello G; Lavacchi D; Antonuzzo L; Catalano M; Mini E
World J Gastroenterol; 2022 Apr; 28(15):1503-1507. PubMed ID: 35582130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
